£7M financing to drive commercialisation in cell and gene therapy
Drug Discovery World
FEBRUARY 21, 2024
Using MIPs’ sophisticated and highly scalable synthetic chemistry approach means they are well positioned to benefit from this tremendous high growth opportunity.” Liz Klein, Investment Director at Calculus, added: “MIP Discovery’s synthetic affinity reagents hold huge potential to overcome bottlenecks in CGT development and production.
Let's personalize your content